Table 3.

HIV-specific risk factors for longer continuous QTc duration (Framingham) among the 774 HIV+ participants^*

	Mean QT difference (ms, 95% CI)	P values
Duration of HAART (years)	0.2 (−0.1 to 0.5)	0.12
Nadir CD4+ T cell count <500 cells/mm³	−2.2 (−5.4 to 1.1)	0.19
Current CD4+ T cell count <500 cells/mm³	−1.0 (−4.2 to 2.1)	0.52
Undetectable HIV RNA viral load (<50 copies/mL)	−2.5 (−6.1 to 1.0)	0.16
History of AIDS	−01.7 (−6.3 to 2.9)	0.48
On protease inhibitors (PI)	0.9 (−2.2 to 4.0)	0.56
Cumulative years of PI use	0 (−0.2 to 0.2)	0.90
On efavirenz	1.0 (−7.0 to 9.1)	0.80
Cumulative years of efavirenz use	−0.1 (−0.3 to 0.2)	0.67
On rilpivirine	11.0 (−2.0 to 24)	0.10
Cumulative years of rilpivirine use	−0.7 (−2.0 to 0.5)	0.26

Each HIV factor was assessed In a separate model with adjustment for age, race, MACS site, wave of MACS enrolment (before/after 2001), body mass Index, heavy alcohol use, cumulative pack-year of smoking, use of opioids, systolic blood pressure, serum fasting glucose level, eGFR, receipt of medications to treat hypertension or diabetes, left ventricular hypertrophy and use of QT prolongation drugs (known and possible vs condition and none).

eGFR, estimated glomerular filtration rate; HAART, highly active antiretroviral therapy; MACS, Multicenter AIDS Cohort Study; QTc, corrected QT interval.